IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.
Complete Dosing Guide
How to Take IGF-1 LR3
For Injectable Administration
Starting Dose:
- 20-30 mcg injected subcutaneously once daily.
- Note: This conservative starting dose allows your body to adjust and helps assess tolerance, especially regarding blood sugar management.
Standard Dosing Protocol:
- Beginners: 20-40 mcg once daily via subcutaneous injection.
- Intermediate Users: 50-80 mcg once daily.
- Advanced Users: 80-100 mcg once daily (in rare cases up to 120 mcg under medical supervision).
- Can be split into two doses (morning and post-workout) for optimal timing.
Cycle Length:
- Standard Cycle: 4-6 weeks of daily use.
- Break Period: 4-6 weeks off between cycles to reset receptor sensitivity.
- Going beyond 6 weeks may lead to receptor desensitization and reduced effectiveness.
- Some protocols use 5 days on, 2 days off pattern within the cycle.
How to Inject:
- Inject subcutaneously (under the skin) using insulin syringes (29-31 gauge, 0.5-1.0 mL capacity).
- Preferred injection sites: abdomen (2 inches from navel), anterior thigh, or posterior upper arm.
- Rotate injection sites daily to prevent lipodystrophy and irritation.
- Insert needle at a 45-90 degree angle into subcutaneous tissue.
- Inject slowly and steadily.
Optimal Timing:
- Post-Workout (Preferred): Within 30 minutes after training to enhance muscle recovery and growth.
- Morning (Fasted): On empty stomach for maximum receptor sensitivity (minimum 2-hour fast).
- Split Dosing: Morning and post-workout if using higher doses (50+ mcg daily).
- Avoid: Do NOT inject less than 2 hours before bedtime to prevent hypoglycemia during sleep and potential suppression of natural growth hormone.
Dosing Calculators
Dose Calculator
Unit Converter
Quick Reference:
Medical Disclaimer
IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.